Carmen Martínez Chamorro

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro et al. · The Lancet Oncology · 2021 · 316 citations

Hematological Malignancy, Oncology, Dexamethasone Versus Pomalidomide +7

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Cyrille Touzeau, Amrita Krishnan, Philippe Moreau et al. · Blood · 2024 · 38 citations · Full text

The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

Naval Daver, Paresh Vyas, Gerwin Huls et al. · Blood · 2025 · 27 citations · Full text

Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience

Ana García‐Noblejas, Carmen Martínez Chamorro, Belén Navarro Matilla et al. · Annals of Hematology · 2014 · 14 citations

Retrospective Study, Lymphoid Neoplasia, Surgical Oncology +6